Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Rondo Therapeutics

Request full access

Bispecific antibody therapies targeting solid tumors

Hayward, United StatesFounded 2021Biotech & Life Sciences

About Rondo Therapeutics

Rondo Therapeutics, Inc. is a biopharmaceutical company founded in 2019 by Shelley Force Aldred, Ph.D. (CEO), and Nathan Trinklein, Ph.D. (President and CSO). The co-founders have a 20-year history of building successful companies together, including Teneobio, which was acquired by Amgen. Their experience at Teneobio, particularly in developing a CD3 T-cell engager platform, informs Rondo's mission to address the unmet need for effective cancer therapies for solid tumors.

The company develops a next-generation immuno-oncology platform focused on creating bispecific antibodies. This class of therapeutic is designed to engage the immune system to fight cancer. While bispecific antibodies have succeeded in treating hematologic (blood) cancers, applying this success to solid tumors has been a significant challenge. Rondo's proprietary approach involves designing antibodies with broad therapeutic windows that can activate and sustain a powerful anti-tumor response while sparing healthy tissue and minimizing toxic side effects. Their technology tunes the potencies of the immune-engaging arms and drives tumor localization to achieve efficacy without dose-limiting toxicities.

Rondo Therapeutics operates on a venture capital-backed business model. In March 2022, the company announced the closing of an oversubscribed $67 million Series A financing round. The round was co-led by Red Tree Venture Capital and Canaan Partners, with participation from Johnson & Johnson Innovation - JJDC, Inc., Novo Holdings A/S, and SV Health Investors. These funds are intended to advance Rondo's lead preclinical programs toward initial Phase 1 clinical studies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
29
Open positions
None listed
Dealroom signal
38.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Mar 2022 $67M $268M Johnson & Johnson Innovation · SV Health Investors · Canaan · Novo Holdings ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Rondo Therapeutics website traffic

Latest recorded traffic for Rondo Therapeutics is 2.8K monthly website visits, up 47.4% over the last three months. Rondo Therapeutics's team declined 9.4% over the past year.

Latest monthly visits2.8K 3-month web change+47.4% 1-year team growth-9.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Rondo Therapeutics in the Hayward ecosystem

Live from Dealroom

The Rondo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Canaan
  • Red Tree Venture Capital
  • Johnson & Johnson Innovation
  • SV Health Investors
  • Novo Holdings
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Rondo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rondo Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.